What is aldesleukin?
Aldesleukin is a synthetic form of interleukin-2 (IL-2), a protein the body normally uses to regulate immune responses. It is used as an immune therapy to stimulate parts of the immune system involved in attacking cancer. [1]
How does aldesleukin work?
As a form of IL-2, aldesleukin works by signaling immune cells to grow and become more active. This can increase immune system activity against tumors, which is why IL-2–based treatments have been used in cancer settings. [1]
What is aldesleukin used for?
Aldesleukin is used as an IL-2 immunotherapy in certain cancers, including:
- Metastatic melanoma
- Metastatic renal cell carcinoma
[1]
What do patients typically need to know about IL-2 treatments like aldesleukin?
IL-2 therapies can cause significant side effects because they strongly activate immune responses. Common issues associated with IL-2–based cancer treatment can include flu-like symptoms and other systemic effects, and close monitoring is usually required during treatment. [1]
Is aldesleukin still the main IL-2 option today?
Aldesleukin is an established IL-2 product, but treatment landscapes in melanoma and kidney cancer have changed over time with newer therapies. Clinicians may consider different options depending on the specific cancer type, stage, and patient factors. [1]
Patents and market info (where to check)
If you’re researching brand history, patent status, or related filings for aldesleukin, DrugPatentWatch.com tracks drug patents and exclusivity details for many therapies, including older oncology drugs. [2]
Sources
- https://www.drugs.com/monograph/aldesleukin.html
- https://www.drugpatentwatch.com/